Revealing Engagement Dynamics Among Diabetic Kidney Disease Patients
NCT06101901 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-10-26
Summary
The study intends to investigate the personal experiences of diabetic kidney disease patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal.
The data collected from this study will help improve future outcomes for all diabetic kidney disease as well as those in under-represented demographic groups.
Conditions
- Diabetic Kidney Disease
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-11-30
- Primary Completion
- 2025-11-30
- Completion
- 2026-11-30
Countries
- United States
Study Locations
More Related Trials
-
Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?
NCT05788276 ·Status: RECRUITING ·Phase: PHASE4
-
The Differential Effects of Diabetes Therapy on Inflammation
NCT02150707 ·Status: COMPLETED
-
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
NCT05671991 ·Status: RECRUITING ·Phase: PHASE4
-
Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients
NCT06606093 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Using a Diabetic Kidney Disease (DKD) Registry to Treat to Multiple Targets (TMT)
NCT02176278 ·Status: COMPLETED ·Phase: NA
-
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
NCT02981966 ·Status: COMPLETED ·Phase: PHASE4
-
Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)
NCT01829256 ·Status: COMPLETED ·Phase: NA
-
A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease
NCT04750577 ·Status: COMPLETED ·Phase: PHASE2
-
OPTIMISE-CKD Drug Utilization
NCT05932901 ·Status: COMPLETED
-
The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
NCT04818034 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
NCT06651021 ·Status: COMPLETED ·Phase: PHASE1
-
Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study
NCT06094231 ·Status: TERMINATED ·Phase: NA
-
Study for the Effectiveness of Intensive Therapy Aiming at a Remission of Diabetic Nephropathy
NCT00253786 ·Status: COMPLETED ·Phase: NA
-
Blood/Urine Markers for Drug Discovery for Renal Disease in Diabetes
NCT02580266 ·Status: WITHDRAWN
-
Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression
NCT07270198 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Transformative Research in Diabetic Nephropathy
NCT02986984 ·Status: RECRUITING
-
Renal Impairment in Type 2 Diabetic Subjects
NCT00554450 ·Status: COMPLETED ·Phase: PHASE1
-
Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
NCT00663260 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes
NCT06532682 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy
NCT04562025 ·Status: UNKNOWN ·Phase: NA
-
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
NCT06610526 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
NCT02413398 ·Status: COMPLETED ·Phase: PHASE3
-
Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease
NCT06694558 ·Status: RECRUITING
-
A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
NCT07239570 ·Status: RECRUITING ·Phase: PHASE4
-
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
NCT06217302 ·Status: RECRUITING ·Phase: PHASE3